PMID- 11488070
OWN - NLM
STAT- MEDLINE
DCOM- 20010823
LR  - 20141120
IS  - 0002-9173 (Print)
IS  - 0002-9173 (Linking)
VI  - 116
IP  - 2
DP  - 2001 Aug
TI  - HER2 protein expression and gene amplification in androgen-independent prostate 
      cancer.
PG  - 234-9
AB  - The role of the HER2 receptor remains uncertain in the pathogenesis and 
      progression of human prostate cancer. Previous studies have reported widely 
      divergent rates for HER2 expression in primary prostate tumors, probably owing to 
      significant methodologic differences in the studies. Few data exist about the 
      frequency of HER2 protein overexpression and gene amplification in 
      androgen-independent prostate cancer (AIPC), although recent xenograft models 
      suggest HER2 expression may be up-regulated in the transition from 
      androgen-dependent to androgen-independent disease. We studied the role of HER2 
      protein in AIPC by immunohistochemical and fluorescence in situ hybridization 
      (FISH) analyses on AIPC specimens using well-characterized and validated 
      reagents. Fourteen (36%) of 39 specimens expressed HER2; however, only 2 (5%) had 
      moderate (2+) expression, and 2 (5%) had high-level (3+) expression. Two (6%) of 
      36 specimens had gene amplification by FISH. These data suggest that HER2 protein 
      overexpression and gene amplification are relatively uncommon in AIPC.
FAU - Reese, D M
AU  - Reese DM
AD  - Urologic Oncology Program, Division of Hematology-Oncology, Comprehensive Cancer 
      Center, University of California, 2356 Sutter St, 5th Floor, San Francisco, CA 
      94115, USA.
FAU - Small, E J
AU  - Small EJ
FAU - Magrane, G
AU  - Magrane G
FAU - Waldman, F M
AU  - Waldman FM
FAU - Chew, K
AU  - Chew K
FAU - Sudilovsky, D
AU  - Sudilovsky D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Androgen Antagonists)
RN  - 0 (Androgens)
RN  - 0 (Antibodies, Monoclonal)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenoma/chemistry/pathology/therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Androgen Antagonists/therapeutic use
MH  - Androgens/*pharmacology
MH  - Antibodies, Monoclonal
MH  - Biopsy
MH  - Bone Neoplasms/chemistry/secondary
MH  - *Gene Amplification
MH  - *Gene Expression
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*chemistry/pathology/therapy
MH  - Receptor, ErbB-2/*analysis/*genetics
EDAT- 2001/08/08 10:00
MHDA- 2001/08/24 10:01
CRDT- 2001/08/08 10:00
PHST- 2001/08/08 10:00 [pubmed]
PHST- 2001/08/24 10:01 [medline]
PHST- 2001/08/08 10:00 [entrez]
AID - 10.1309/VXKK-YVRH-9B11-YDPT [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2001 Aug;116(2):234-9. doi: 10.1309/VXKK-YVRH-9B11-YDPT.